41.00
-0.31 (-0.75%)
| Previous Close | 41.31 |
| Open | 41.06 |
| Volume | 542,323 |
| Avg. Volume (3M) | 459,655 |
| Market Cap | 1,417,329,024 |
| Price / Book | 3.21 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.96 |
| Total Debt/Equity (MRQ) | 6.76% |
| Current Ratio (MRQ) | 21.17 |
| Operating Cash Flow (TTM) | -93.93 M |
| Levered Free Cash Flow (TTM) | -61.01 M |
| Return on Assets (TTM) | -18.75% |
| Return on Equity (TTM) | -27.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Disc Medicine, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.32% |
| % Held by Institutions | 79.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 31 Dec 2024 | 2,509,456 |
| Frazier Life Sciences Management, L.P. | 31 Dec 2024 | 1,754,834 |
| Paradigm Biocapital Advisors Lp | 31 Dec 2024 | 1,497,720 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2024 | 983,500 |
| Saturn V Capital Management Lp | 31 Dec 2024 | 509,406 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 132.00 (Cantor Fitzgerald, 221.95%) | Buy |
| Median | 94.00 (129.27%) | |
| Low | 75.00 (Scotiabank, 82.93%) | Buy |
| Average | 100.80 (145.85%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 56.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 18 Mar 2025 | 132.00 (221.95%) | Buy | 52.83 |
| Morgan Stanley | 07 Mar 2025 | 85.00 (107.32%) | Buy | 55.67 |
| Scotiabank | 03 Mar 2025 | 75.00 (82.93%) | Buy | 54.33 |
| 22 Jan 2025 | 73.00 (78.05%) | Buy | 58.50 | |
| Stifel | 24 Jan 2025 | 94.00 (129.27%) | Buy | 57.45 |
| HC Wainwright & Co. | 21 Jan 2025 | 118.00 (187.80%) | Buy | 60.52 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| QUISEL JOHN D | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| QUISEL JOHN D | Officer | 07 Apr 2025 | Option execute | 7,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 27 Feb 2025 | Announcement | Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 26 Feb 2025 | Announcement | Disc Medicine to Participate in Upcoming Investor Conferences |
| 22 Jan 2025 | Announcement | Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants |
| 21 Jan 2025 | Announcement | Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission |
| 21 Jan 2025 | Announcement | Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 20 Jan 2025 | Announcement | Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |